Population Attributable Fraction Estimates of Cardiovascular Diseases in Different Blood Pressure Levels in a Large-Scale Cross-Sectional Study: A Focus on Prevention Strategies and Treatment Coverage Publisher Pubmed



Keykhaei M^{1, 2} ; Rezaei N^{1, 3} ; Roshani S¹ ; Montazeri F¹ ; Nasserinejad M^{1, 4} ; Azadnajafabad S¹ ; Mohammadi E¹ ; Ghasemi E¹ ; Rezaei N^{1, 3} ; Farrokhpour H¹ ; Foroumadi R⁵ ; Bagheri S⁵ ; Moghimi M¹ ; Larijani B³ Show All Authors Show Affiliations
Source: Blood Pressure Monitoring Published:2023

Abstract

Objective Hypertension is one of the major modifiable risk factors in developing cardiovascular diseases (CVD). Hence, we aimed to ascertain age- and sex-specific population attributable fraction (PAF) for CVD in different blood pressure levels to implement efficient preventive strategies at the population level. Methods Participants' data were obtained from the Iranian stepwise approach for surveillance of noncommunicable disease risk factors (STEPs) survey to calculate PAF in four subsequent phases. In phase 0, PAF was measured, irrespective of the diagnosis status. In phase 1, the theoretical minimum range of 115 ≤SBP less than 130 mmHg was considered as the low-risk and measurements equal to or higher than 130 mmHg as the high-risk group. Across phase 2, patients were divided into normal and hypertensive groups based on the American College of Cardiology/American Heart Association guideline. In phase 3, patients were divided into two categories based on treatment coverage. Results A total number of 27 165 participants aged ≥25 years had valid blood pressure measurements and were enrolled. Phase 0: PAF generally had an upward trend with age advancing. Phase 1: participants with BP ≥130 mmHg comprised the largest PAF, extending from 0.31 (0.25-0.37) in older male individuals to 0.85 (0.79-0.91) in younger females. Phase 2: higher values were found in younger ages for hypertension. Phase 3 represented that attributable fractions among hypertensive patients who received treatment were much lower than drug-naive hypertensive participants. Conclusion Our study enlightens the necessity for implementing effective screening strategies for the younger generation and providing adequate access to antihypertensive medications for the low-risk population. Copyright © 2022 Wolters Kluwer Health, Inc.